TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a phase II trial of 18 breast cancer survivors, participants who took oxaloacetate for eight weeks reported improved cognitive symptoms and less fatigue. The early results are promising but do not establish that the supplement caused the changes; larger studies are needed.
A small clinical trial led by researchers at UCLA Health Jonsson Comprehensive Cancer Center found that breast cancer survivors taking the supplement oxaloacetate for eight weeks reported improvements in brain fog and fatigue. The phase II study included 18 women, and the researchers say larger trials are needed to determine whether the supplement is effective.
The women took 500 milligrams twice daily. Sixteen of the 18 participants completed the full eight weeks, and all 16 reported improvement in cognitive symptoms. On the study’s main measure of perceived cognitive impairment, the group’s average score increased from 29.1 before treatment to 55.5 after eight weeks, which the researchers said was within the range considered normal rather than impaired. Improvement was apparent at four weeks and generally grew over the treatment period.
Participants also reported less fatigue and better physical functioning. Standardized tests showed improvement in processing speed and executive function, which includes abilities such as planning, maintaining attention and managing tasks. The team tracked symptoms through participant questionnaires and cognitive tests, and monitored possible side effects. Oxaloacetate was generally well tolerated during the study; reported side effects most often involved digestion.
The findings were published in JCO Oncology Advances. The report describes an early, small trial, not evidence that oxaloacetate is an established treatment. With no larger confirmatory study described in the source, the results cannot show how well the supplement would work for a broader group of survivors or whether the reported changes were caused by the supplement.
A Possible Option for Persistent Symptoms
Cognitive problems after cancer treatment can affect everyday activities, including concentration, memory and organizing tasks. The study’s lead author, Dr. Patricia Ganz, said such impairment can continue after treatment and that effective treatments remain limited. The reported changes in both participants’ symptom ratings and some test results make oxaloacetate a candidate for further research, rather than a treatment survivors can rely on based on this trial alone.
The results may matter to survivors who continue to experience mental fatigue or difficulty thinking after care ends. But the study’s 16 completers represent a small group, and the findings do not establish the supplement’s effectiveness, long-term safety or suitability for individual patients. People considering supplements for cancer-related symptoms should discuss medical decisions with a qualified health professional.
Popular right now
Dyson Airwrap i.d. Multi-Styler for Straight and Wavy Hair
Ninja DualZone Air Fryer 10 Qt Smart 6-in-1 Grey
Apple AirPods Pro (2nd Generation) Wireless Earbuds with USB‑C Charging, Up to 2X More Active Noise Cancelling, Transparency Mode, Adaptive
As an affiliate, we earn on qualifying purchases.
Who Was Studied and Why
The trial enrolled women diagnosed with early-stage breast cancer one to five years earlier. Participants were about 50 years old on average, had substantial cognitive difficulties at enrollment, and most had received chemotherapy. Nearly 90% were still receiving endocrine therapy during the study.
Researchers estimate that roughly 15% to 25% of breast cancer survivors experience ongoing problems with memory, concentration or other thinking abilities after diagnosis and treatment. The symptoms are often called “chemo brain,” although chemotherapy is not necessarily the only cause. Cancer, treatment, inflammation, hormonal changes and other factors may all contribute.
The UCLA team focused on oxaloacetate because it occurs naturally in the body and has roles in cellular energy production and glutamate regulation. The researchers proposed that these functions could be relevant to processes affecting brain activity, but the trial tested reported symptoms and cognitive performance; it does not establish how the supplement might produce any changes.
“Cancer-related cognitive impairment can persist long after treatment ends and can have a significant impact on a person’s daily life, yet we still have very few effective treatments for it.”
— Dr. Patricia Ganz, the study’s first author and a professor at UCLA
What the Small Trial Cannot Show
The study had 18 participants, with 16 completing treatment, and the source characterizes the results as preliminary. The available report does not establish whether the trial included a comparison group or whether participants knew they were taking oxaloacetate; without those details, it is not possible to assess how those factors may have influenced the reported improvements.
It is also unclear how long any benefits lasted after the eight-week period, whether results would extend to people with other cancers or treatment histories, and what the supplement’s safety profile might be with longer use. The source says digestive complaints were the most common reported side effects but does not give a detailed breakdown. Larger studies are needed to confirm the findings and clarify these questions.
Larger Studies Must Test the Findings
The next step is further research with more participants to test whether oxaloacetate produces reliable improvements and to examine its safety over longer periods. The source does not provide a schedule for a follow-up trial or say when additional results may be available. Until stronger evidence emerges, the eight-week findings should be treated as early research, not proof that the supplement clears brain fog after cancer.
Key Questions
What is oxaloacetate?
Oxaloacetate is a molecule that occurs naturally in the body and plays a role in cellular energy production. The UCLA team also studied its connection to glutamate regulation.
How many people took part in the trial?
The phase II trial enrolled 18 women who had experienced early-stage breast cancer; 16 completed the eight-week supplement period.
What improvements did participants report?
Those who completed the trial reported improved cognitive symptoms, including difficulties with thinking, and less fatigue. Tests also showed improvements in processing speed and executive function, but the small study does not confirm that the supplement caused these changes.
Does this mean oxaloacetate is a proven treatment for brain fog?
No. The findings are preliminary and come from a small trial. Larger studies are needed before the supplement’s effectiveness and longer-term safety can be established.
Source: sciencedaily.com
